Clinical decision-making is a complex process, driven by multiple factors, including social and psychological dynamics, peer pressure and even exposure to drug advertising. Now research from Harvard ...

Insomnia is a significant health and quality of life concern for older adults, with up to half of all adults over the age of 65 experiencing insomnia symptoms. In a new study, researchers in the Penn ...

This Nature Outlook is editorially independent, produced with financial support from Avadel. Miranda cannot remember a time in her life when she did not have insomnia. The 23 year old, who asked for ...

The Food and Drug Administration has recommended that the bedtime dose of the insomnia drug zolpidem be lowered because there's new evidence that, after taking the current dose, the level of drug ...

TOKYO, May 28, 2025 - (JCN Newswire) - - Eisai Co., Ltd. announced today that the in-house-discovered and developed orexin receptor antagonist DAYVIGO (generic name: lemborexant) has been approved in ...

The U.S. Food and Drug Administration approved Belsomra (suvorexant) tablets for use as needed to treat insomnia. Belsomra is an orexin receptor antagonist and is the first approved drug of this type.

As far back as the 1800s, patients were prescribed medication for insomnia. While barbiturates were popularized in the early 1900s, they were soon replaced by benzodiazepines, such as Valium (1960s ...

The "Insomnia: Opportunity Assessment and Forecast Update" report has been added to ResearchAndMarkets.com's offering. This report covers the 7MM and provides an Excel-based forecast model for the ...

The "frustrating" condition may affect as much as 66% of the population.